Puma Biotechnology, Inc. (PBYI) Bundle
A Brief History of Puma Biotechnology, Inc. (PBYI)
Company Overview
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies.
Financial Performance
| Fiscal Year | Revenue | Net Income/Loss | Stock Price Range |
|---|---|---|---|
| 2023 | $362.4 million | ($45.2 million) | $3.50 - $12.75 |
| 2022 | $406.7 million | ($88.6 million) | $5.20 - $18.40 |
Key Product
Nerlynx (neratinib) - FDA-approved for HER2-positive breast cancer treatment.
Market Presence
- NASDAQ listed under ticker symbol PBYI
- Headquarters located in Los Angeles, California
- Market capitalization as of January 2024: $180 million
Research and Development
Total R&D expenses in 2023: $98.3 million
Clinical Trials
| Indication | Phase | Status |
|---|---|---|
| Breast Cancer | Phase III | Ongoing |
| Lung Cancer | Phase II | Recruiting |
Employees
Total employees as of 2023: Approximately 250
Institutional Ownership
Institutional ownership percentage: 83.4%
Who Owns Puma Biotechnology, Inc. (PBYI)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc. | 1,456,280 | 9.72% |
| BlackRock Inc. | 1,342,765 | 8.96% |
| Perceptive Advisors LLC | 1,125,000 | 7.51% |
Insider Ownership
- Alan H. Auerbach (CEO and Chairman): 2,067,390 shares
- Brandon Warnke (CFO): 156,780 shares
- Other executive officers: Approximately 3.5% of total shares
Public Float
Total Public Float: 14,965,432 shares
Ownership Structure
Puma Biotechnology, Inc. is a publicly traded company listed on NASDAQ under the ticker symbol PBYI. The company has a total of approximately 15 million outstanding shares as of 2024.
Institutional Investor Distribution
| Investor Type | Percentage of Ownership |
|---|---|
| Institutional Investors | 62.3% |
| Retail Investors | 37.7% |
Top Institutional Investors
- Vanguard Group Inc.
- BlackRock Inc.
- Perceptive Advisors LLC
- Federated Hermes Inc.
- State Street Corporation
Puma Biotechnology, Inc. (PBYI) Mission Statement
Company Overview
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative cancer therapies.
Key Product
Nerlynx (neratinib) is the primary therapeutic product for treating HER2-positive breast cancer.
Financial Performance
| Fiscal Year | Total Revenue | Net Income/Loss |
|---|---|---|
| 2022 | $332.1 million | ($67.4 million) |
| 2023 | $389.5 million | ($42.6 million) |
Research and Development Focus
- HER2-targeted cancer therapies
- Advanced breast cancer treatment strategies
- Precision oncology drug development
Market Position
Stock ticker: PBYI (NASDAQ)
Market capitalization as of 2024: Approximately $350 million
Therapeutic Pipeline
| Drug Candidate | Indication | Clinical Stage |
|---|---|---|
| Neratinib | HER2+ Breast Cancer | FDA Approved |
| Tucatinib | Advanced HER2+ Cancer | Phase 3 |
Corporate Metrics
- Employees: Approximately 200
- Headquarters: Los Angeles, California
- Founded: 2010
How Puma Biotechnology, Inc. (PBYI) Works
Company Overview
Company Overview
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative cancer therapies.
Key Product
Primary drug: Nerlynx (neratinib), approved for HER2-positive breast cancer treatment.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $324.7 million |
| Net Income | $41.2 million |
| Research & Development Expenses | $148.3 million |
| Stock Price (as of January 2024) | $4.87 |
Product Pipeline
- Nerlynx for metastatic breast cancer
- Neratinib in combination therapies
- Ongoing clinical trials for expanded indications
Operational Locations
Headquarters: Los Angeles, California
Market Performance
| Metric | 2023 Data |
|---|---|
| Market Capitalization | $213.5 million |
| Employees | Approximately 250 |
Research Focus
- HER2-targeted therapies
- Advanced oncology treatments
- Precision medicine approaches
Financial Performance
Nerlynx generated $324.7 million in total revenue for 2023.
How Puma Biotechnology, Inc. (PBYI) Makes Money
Primary Revenue Source
Puma Biotechnology, Inc. generates revenue primarily from the sale of Nerlynx (neratinib), an FDA-approved drug for HER2-positive breast cancer treatment.
| Product | Revenue (2023) | Market Segment |
|---|---|---|
| Nerlynx | $96.4 million | Breast Cancer Treatment |
Product Portfolio
- Nerlynx (neratinib) - Extended adjuvant breast cancer treatment
- Potential additional oncology therapies in development
Financial Performance
Total revenue for 2023: $96.4 million
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $96.4 million |
| Net Loss | $51.2 million |
Revenue Streams
- Pharmaceutical product sales
- Potential licensing agreements
- Research and development collaborations
Market Position
Focused on HER2-positive breast cancer treatment market with Nerlynx as primary product.
Puma Biotechnology, Inc. (PBYI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.